In the future, we need to conduct more in-depth research on this topic due to the prevalence of PTEN inactivation in tumors, which not only will contribute to the treatment of NSCLC but may also benefit the treatment of other tumors. The gene discussed is PTEN; the disease is non-small cell lung carcinoma.